The PERLA trial showed consistent OS benefits across various PD-L1 tumor proportion scores, favoring Jemperli over Keytruda.

Side effects were "generally manageable," according ... For comparison, the KEYNOTE-042 trial, which first established Keytruda monotherapy as the standard of care for PFD-L1-high NSCLC, showed ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...

We estimate that nearly half this amount or $45 million will come from purely mathematical and contractual annual rate ...

Markets rallied strongly this week as investors got a clear outcome in the presidential election and an expected interest rate cut by the Federal Reserve. Is this a relief rally, the continuation of a ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Drugs like pembrolizumab (Keytruda) can be used in combination with chemotherapy to enhance the immune response against cancer. Radiation Therapy: Radiation therapy uses high-energy rays to target and ...

An expert told CURE that Trodelvy's side effects, such as neutropenia and fatigue, can often be managed through dose ...

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that ...

As of September 30, 2024, the Company had approximately $32.4 million in cash and cash equivalents compared with $48.5 ...